RA Capital Healthcare Fund LP's Form 4 filing
SpyGlass Pharma, Inc. (SGP) · filed Feb 11, 2026
- Accession no.
- 0001231919-26-000135
- Filed
- Feb 11, 2026, 5:15 PM ET
- Trade date
- Feb 9, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 6 derivative transactions. Open-market purchases total $59.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund III, L.P.CIK 0001883840 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionAcquired | +2,524,473 | –F1 | – | 2,524,473 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionAcquired | +1,806,644 | –F1 | – | 1,806,644 | Indirect | |
| Feb 9, 2026 | Common Stock | PPurchaseAcquired | +3,441,966 | $16.00 | +$55,071,456 | 5,966,439 | Indirect | |
| Feb 9, 2026 | Common Stock | PPurchaseAcquired | +248,034 | $16.00 | +$3,968,544 | 2,054,678 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,150,941 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −767,294 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −1,150,941 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −767,294 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −222,591 | –F1 | – | 0 | Indirect | |
| Feb 9, 2026 | Common Stock | CConversionDisposed | −272,056 | –F1 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Referenced by the price of 2 transactions in Table I and 6 transactions in Table II.
Remarks
Dr. Zachary Scheiner, a Principal of the Adviser, serves on the Issuer's board of directors.